MOTS-C

A MOTS-C 40mg vial contains 40 milligrams of the 16-residue mitochondrial-derived peptide as a white lyophilised powder, four times the content of the standard 10mg vial. Molecular formula C₁₀₁H₁₅₂N₂₈O₂₂S₂, molecular weight 2174.5 g/mol, CAS 1627580-64-6, sequence MRWQEMGYIFYPRKLR. Batch UKPL-9022 is verified at 98.896% purity with the certificate of analysis published on this page.

Only in the mass of peptide per vial. It is the same compound, the same sequence and the same lyophilised powder, at four times the content. The practical differences are that a 40mg vial reaches four times the concentration at a given reconstitution volume, that all 40mg shares one in-use window and one reconstitution date once opened, and that a single batch and certificate of analysis covers four times as much work.

Because the oxidation-sensitive side chains in the sequence are exposed for longer. MOTS-C carries two methionine residues, one tryptophan and two tyrosines, all of which are oxidation-labile. A vial holding four times the mass is usually consumed over a longer period and across more stopper penetrations, so a single reconstituted stock accumulates more headspace air contact, more light exposure and more freeze-thaw cycles. Drawing single-use aliquots at the point of reconstitution isolates each withdrawal from that history.

That depends entirely on the concentration your protocol specifies, so there is no fixed figure and we do not provide dosing information. The arithmetic is mass divided by volume: 40mg reconstituted with 4mL gives a 10mg/mL stock, and the same 40mg in 2mL gives 20mg/mL. Because a 40mg vial reaches four times the concentration of a 10mg vial at identical fill volume, volumes should not be carried over unchanged between the two sizes.

Yes. Both vials contain the identical 16-residue peptide, MRWQEMGYIFYPRKLR, at 2174.5 g/mol, and neither is a modified analogue or a different sequence. The 40mg vial is not a stronger material, it simply holds more of it. Each vial size carries its own batch number and its own published certificate of analysis, so the purity figure quoted for the 40mg vial applies to that batch specifically rather than being inherited from the 10mg batch.

The current MOTS-C 40mg batch is UKPL-9022, verified at 98.896% purity by HPLC, and the full third-party certificate of analysis is published on this product page rather than provided on request. Check that the batch number on the vial matches the certificate, and that the report carries a quantity assay confirming 40mg of content, since purity alone says nothing about how much peptide is actually in the vial.

UK Peptide Lab supplies MOTS-C 40mg in the UK, batch UKPL-9022 at 98.896% purity, third-party tested with the certificate of analysis published on this page, and dispatched the same day on orders placed before 3pm UK time. Free UK Royal Mail Tracked shipping on orders over £69. Stock on this larger format is limited. Purchasers must be 18 or over and confirm research-only use. Not for human consumption or any therapeutic application.

Batch UKPL-9022 was tested by Janoshik Analytical at 98.896% purity by RP-HPLC, against a ≥98.0% specification. Content quantification found 42.96mg against 40mg declared. Each vial size has its own batch and certificate, so this figure is not inherited from the 10mg batch.

For batch continuity and cost per milligram. One 40mg vial is one batch under one certificate, so a large study runs against a single purity figure. Per-vial costs such as lyophilisation, stopper and third-party assay spread across more milligrams. The counter-argument is exposure, since all 40mg shares one in-use window, which aliquoting answers.